Ascelia Pharma AB
F:7ZA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ascelia Pharma AB
F:7ZA
|
SE |
|
N
|
Netlist Inc
F:XAB
|
US |
|
Experience Co Ltd
ASX:EXP
|
AU |
|
J
|
Japan Post Holdings Co Ltd
F:1JP
|
JP |
|
Ebara Jitsugyo Co Ltd
F:EJI
|
JP |
|
C
|
Chaosua Foods Industry PCL
SET:CHAO
|
TH |
|
N
|
North East Rubber PCL
SET:NER
|
TH |
Intrinsic Value
Is 7ZA undervalued or overvalued?
See the intrinsic value estimate for 
Ascelia Pharma AB and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
7ZA looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with 7ZA’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Ascelia Pharma AB Does
Ascelia Pharma is a Swedish biotech company that develops medicines for rare cancer-related conditions. Its lead project is Orviglance, an oral contrast agent designed to improve liver MRI scans for patients who cannot use standard gadolinium-based contrast agents, such as people with serious kidney problems. The company is still focused on development and regulatory work rather than broad commercial sales.
- Headquarters
- Sweden SE
- Employees
- 21
- IPO date
- Mar 13, 2019
Revenue & Expenses Breakdown
Ascelia Pharma AB
Earnings Waterfall
Ascelia Pharma AB
The intrinsic value for Ascelia Pharma AB (7ZA) under the Base Case is hidden EUR.
Compared with the current market price of 0.0378 EUR, the stock appears hidden.